LOGIN
Pre-op and post-op osocimab non-inferior to enoxaparin for reducing the incidence of VTE after TKA
February 2020
Pre-op and post-op osocimab non-inferior to enoxaparin for reducing the incidence of VTE after TKA
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial
JAMA. 2020 Jan 14;323(2):130-139.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Eight hundred and thirteen patients scheduled for a total knee arthroplasty were randomized to receive a single post-operative dose of osocimab (0.3, 0.6, 1.2, 1.8mg/kg) or a pre-operative dose of osocimab (0.3, 1.8mg/kg) for the reduction of thromboembolic events, compared to enoxaparin or apixaban. The primary time-point was at the time of venography (approximately 10-13 days post-operation). Re...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.